Gainers
-
MacroGenics, Inc. (NASDAQ: MGNX)
jumped 150.2 percent to $27.80 after reporting positive results from pivotal Phase 3 SOPHIA study of margetuximab.
-
Novelion Therapeutics Inc (NASDAQ: NVLN) climbed 48 percent to $1.42 after the company announced a licensing
agreement in which Novelion's subsidiary company will receive $25 million and 22.5 percent in royalties on JUXTAPID sales in
Japan.
-
Snap Inc. (NYSE: SNAP) shares gained
25.7 percent to $1.42 after the company reported stronger-than-expected earnings and sales for its fourth quarter.
-
Proteostasis Therapeutics, Inc. (NASDAQ: PTI) rose 17.4 percent to $3.65. Proteostasis Therapeutics appointed Emmanuel
Dulac and Kim Drapkin to its Board of Directors.
-
Skyline Champion Corporation (NYSE: SKY)
shares climbed 15.6 percent to $19.48 following Q3 earnings. Skyline posted Q3 earnings of $0.27 per share on sales of $354.7
million.
-
Plantronics, Inc. (NYSE: PLT) rose 14.5
percent to $45.76 after reporting upbeat Q3 earnings.
-
Zai Lab Limited (NASDAQ: ZLAB) gained
14.2 percent to $31.47 after MacroGenics reported positive margetuximab, as Zai Lab owns development and commercialization
rights to margetuximab in multiple regions.
-
Skyline Champion Corporation (NYSE: SKY)
shares climbed 12.5 percent to $18.95 following Q3 results.
-
Bionano Genomics, Inc. (NASDAQ: BNGO)
shares rose 12.2 percent to $4.2750 after the company disclosed that its Saphyr system is used for highly accurate detection of
the genetic disorder FSHD as an alternative to southern blot.
-
Skyworks Solutions, Inc. (NASDAQ: SWKS) climbed 11.4 percent to $84.65 following Q1 earnings.
-
Capri Holdings Ltd (NYSE: CPRI) gained
11.3 percent to $48.49 after the company said it expects Q4 sales of $1.33 billion versus the $1.21 billion analyst estimate.
-
Canadian Solar Inc. (NASDAQ: CSIQ)
shares rose 10.9 percent to $21.94. Canadian Solar raised its Q4 sales guidance.
-
MaxLinear, Inc. (NYSE: MXL) jumped 9.5
percent to $21.62 following upbeat Q4 results.
-
PCM, Inc. (NASDAQ: PCMI) surged 9.4
percent to $24.18 following Q4 results.
-
Microchip Technology Incorporated (NASDAQ: MCHP) gained 9.2 percent to $90.92 after the company reported upbeat Q3
earnings.
-
Paycom Software, Inc. (NYSE: PAYC)
climbed 9.1 percent to $171.23 after reporting a fourth-quarter earnings beat.
-
Viavi Solutions Inc (NASDAQ: VIAV)
rose 8.7 percent to $11.87 after reporting a second-quarter earnings beat.
-
Zendesk, Inc. (NYSE: ZEN) climbed 8.4
percent to $74.35 after reporting upbeat Q4 results.
-
Identiv, Inc. (NASDAQ: INVE) gained
8.4 percent to $5.58.
-
SPI Energy Co., Ltd. (NASDAQ: SPI)
shares surged 7.1 percent to $3.1909.
-
ING Groep N.V. (NYSE: ING) rose 6.2
percent to $12.68 following Q4 earnings.
-
Eyenovia Inc (NASDAQ: EYEN) gained 4.3
percent to $4.36 after the company reported FDA acceptance of IND application for micropine to reduce the progression of
myopia.
Check out these big penny stock gainers and
losers
Losers
-
Arlo Technologies, Inc. (NASDAQ: ARLO)
shares dipped 43.3 percent to $4.29 after reporting wider-than-expected Q4 loss.
-
Phunware Inc. (NASDAQ: PHUN) shares
fell 34.9 percent to $137.50.
-
Calix, Inc. (NYSE: CALX) declined 25.9
percent to $8.06. Calix posted upbeat Q4 earnings, while sales missed estimates.
-
Container Store Group Inc (NYSE: TCS)
dropped 24.5 percent to $5.88 after third-quarter earnings and sales missed estimate. The company also guided full-year sales
at the lower end of the range.
-
CCA Industries, Inc. (NYSE: CAW) fell
22.2 percent to $1.8587 after the company announced it will deregister its shares from the NYSE.
-
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) shares dipped 20.3 percent to $4.82. Catabasis priced its 4 million
common unit offering at $5 per unit.
-
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) fell 18.1 percent to $20.54. Vanda Pharmaceuticals filed a complaint
against FDA for requiring studies in animals without legal authority. Cantor Fitzgerald downgraded Vanda Pharma from Overweight
to Neutral.
-
FNCB Bancorp, Inc. (NASDAQ: FNCB)
dropped 17.2 percent to $7.50. FNCB Bancorp reported pricing of 2.857 million share common stock offering at $20 per share.
-
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) fell 15.9 percent to $7.91 after the company priced a 3.75 million share
common stock offering at $8 per share.
-
MACOM Technology Solutions Holdings, Inc. (NASDAQ: MTSI) tumbled 15.4 percent to $15.42 after reporting Q1 results.
-
Integrated Media Technology Limited (NASDAQ: IMTE) dropped 14.8 percent to $8.52.
-
USANA Health Sciences, Inc. (NYSE: USNA)
fell 12.9 percent to $102.12 after reporting Q4 results.
-
Electronic Arts Inc. (NASDAQ: EA) fell
12.8 percent to $80.66 after the company reported weaker-than-expected revenue for its third quarter and lowered its yearly
revenue guidance.
-
PHI, Inc. (NASDAQ: PHII) dropped 12.3
percent to $4.79.
-
Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell 10.3 percent to $96.23 after the company issued weak revenue
forecast.
-
Shutterfly, Inc. (NASDAQ: SFLY) fell
10.2 percent to $40.59 after the company reported downbeat results for its fourth quarter. The company disclosed that CEO
Christopher North will step down.
-
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) dropped 9.3 percent to $5.19.
-
UGI Corporation (NYSE: UGI) shares
declined 9.3 percent to $51.65 following downbeat quarterly earnings.
-
Healthcare Services Group, Inc. (NASDAQ: HCSG) fell 8.7 percent to $38.51 after reporting Q4 earnings.
-
Tenable Holdings, Inc. (NASDAQ: TENB)
shares declined 8.2 percent to $26.82 following Q4 earnings.
-
Activision Blizzard, Inc. (NASDAQ: ATVI) fell 8.1 percent to $43.96 after rising 2.27 percent on Tuesday.
-
Coffee Holding Co., Inc. (NASDAQ: JVA)
dropped 8 percent to $6.43.
-
Aphria Inc. (NYSE: APHA) fell 7 percent
to $9.97 after the company’s board rejected Green Growth Brand's hostile takeover bid.
-
Cronos Group Inc. (NASDAQ: CRON) fell
6.2 percent to $20.48.
-
Pinduoduo Inc (NASDAQ: PDD) dropped 4.4
percent to $29.00 after the company announced a 51.9 million share offering.
-
Markel Corporation (NYSE: MKL) shares
fell 4.4 percent to $1,022.74 after reporting 2018 results.
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.